Financials
Financial year 2025
BIO - VITALPHARMA from Antwerpen, company number BE0452775313, closed financial year 2025 with a result of € 119,591 after tax. For that financial year BIO - VITALPHARMA recorded a gross margin of € 250,808 and equity of € 207,480. Compared with financial year 2024, the result moved from € 101,161 to € 119,591. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 28, 2026.
€ 207,480
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 119,591
▲ 18% vs 2024
Profit after tax over the fiscal year.
€ 85,573
▼ 3% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 119,000 paid out
100 % of the profit went to the shareholders, mostly to Be-Lieve (100 % of the shares). That is where the money ends up.
People and assets in 2025
2.2
▼ 0.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 115,649
▼ 4% vs 2024
€ 52,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,468
▲ 296% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 88,613
€ 11,872 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 101,661
▼ 23% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 13,691
▲ 4% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 207,301 | € 215,730 | € 245,316 | € 250,808 | ▲ 2% |
| Profit after taxes | € 77,565 | € 84,970 | € 101,161 | € 119,591 | ▲ 18% |
| Equity | € 201,757 | € 206,728 | € 206,889 | € 207,480 | |
| Total debts | € 342,974 | € 371,037 | € 336,468 | € 324,541 | ▼ 4% |
| Cash | € 104,140 | € 36,685 | € 88,414 | € 85,573 | ▼ 3% |
| Retained profit | € 99,471 | € 104,441 | € 104,602 | € 105,193 | ▲ 1% |
| Dividend | € 70,000 | € 80,000 | € 101,000 | € 119,000 | ▲ 18% |
| Bank debt | € 108,500 | € 98,612 | € 88,521 | € 88,613 | |
| Balance sheet total | € 544,731 | € 577,764 | € 543,356 | € 532,020 | ▼ 2% |
| Employees (FTE) | 2.2 | 2 | 2.8 | 2.2 | ▼ 0.6 |
Key figures of BIO - VITALPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BIO - VITALPHARMA?
What happened at BIO - VITALPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Ellen Hilgert stepped down as director. NBB
- BE-LIEVE BV stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 119,591 (▲ 18% vs 2024). Source: NBB ↗
- Ellen Hilgert became a director. NBB
- BE-LIEVE BV became a director. NBB
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
In short
From € 77,565 profit in 2022 to € 119,591 profit in 2025.
Paid € 2,615 in corporate taxes since 2022.
Best year ever: 2025, with € 119,591 profit.
On average € 114,000 of value added per employee in 2025.
A new publication or filing at BIO - VITALPHARMA? We notify you, reason included.
Follow BIO - VITALPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Be-Lieve comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BIO - VITALPHARMAThe shares are held by Be-Lieve (99.9%).
Directors
According to the 2025 annual accounts
since 2023 · until 2029
Director · represented by Lieve Vercauteren
since 2023 · until 2029
Shareholders
99.9%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Turnhoutsebaan 282
2140 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
AMAZON-02 - Amazon.com, Inc., US
Website info
Features
Security
Details
- Company number
- 0452.775.313
- VAT number
- BE 0452.775.313
- Registered office
- Turnhoutsebaan 282, 2140 Antwerpen
- Names & denominations
- BIO - VITALPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 31 May 1994
- Peppol
- Active · Active since 17 Mar 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels